Latest News and Updates | Cantargia

* (R) = Regulatory press releases

Aug 19, 2021

(R) Cantargia expands CIRIFOUR trial after successful completion of recruitment in the pembrolizumab combination arm

Aug 19, 2021

(R) Cantargia publishes half year report

Aug 10, 2021

Invitation to presentation of Cantargia’s report for the second quarter of 2021 on August 19 at 3.00 p.m. CET

Jul 1, 2021

(R) Cantargia advances development of nadunolimab in triple negative breast cancer through submission of clinical protocol for TRIFOUR study

Jul 1, 2021

(R) Cantargia advances development of nadunolimab in triple negative breast cancer through submission of clinical protocol for TRIFOUR study

Jun 29, 2021

(R) Cantargia broadens the development of nadunolimab in three forms of cancer and submits application for the phase I/II clinical trial CESTAFOUR

Jun 8, 2021

(R) Cantargia receives regulatory approval to start clinical trial investigating nadunolimab and FOLFIRINOX in pancreatic cancer

May 26, 2021

(R) Annual General Meeting in Cantargia AB (publ)

May 26, 2021

(R) Cantargia publishes interim report for first quarter 2021

May 19, 2021

(R) Cantargia reports positive results in ongoing phase IIa clinical trial in pancreatic cancer using nadunolimab and chemotherapy

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye